Invest in intelligence that delivers

Regeneron and Genentech battle for ophthalmologists’ affinity in Eylea HD, Vabysmo matchup

After seven months on the market, Regeneron’s Eylea HD is already making strides with ophthalmologists. According to Spherix Global Insights’ research, 81% of ophthalmologists who use Eylea HD to treat wet age-related macular degeneration (AMD) are “highly satisfied,” which tracks closely to the 87% who say the same about Roche and Genentech’s Vabysmo, which has […]

US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies

Research conducted by Spherix Global Insights reveals Retinal Specialists likely to adopt gene therapies. Exton, PA., March 19, 2024 – Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising pathway for delivering genetic material with precision and […]

Stakes Are High for Regeneron’s Eylea HD as Genentech’s Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights

Navigating the landscape of Wet AMD Therapies During AMD Awareness Month EXTON, PA., February 8, 2024 — As Age-Related Macular Degeneration (AMD) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD, the need for optimal treatment solutions becomes increasingly evident. Wet AMD poses a particularly severe threat to vision, necessitating […]

“I Need to See It With My Own Eyes”: How US Ophthalmologists React to Apellis’ Syfovre Safety Warnings When Managing Geographic Atrophy

Ophthalmologists’ reservations about using Syfovre in Geographic Atrophy are more limited to “new start” patients, according to Spherix Global Insights.  [Exton PA, December 14, 2023] — Geographic Atrophy (GA), the most severe stage of dry age-related macular degeneration (dAMD), poses a significant challenge as retinal cells atrophy, resulting in irreversible lesions that impact central vision. […]

Despite Impressive Early Uptake of Apellis’ Syfovre in Geographic Atrophy, US Ophthalmologists Struggle to Articulate the Complement Inhibitor’s Value Proposition to Potential Patients

Lack of vision improvement, amongst other efficacy concerns, as well as potential for conversion to neovascular age-related macular degeneration are among core barriers limiting Syfovre uptake, according to Spherix Global Insights. EXTON, Pa., June 28, 2023 –With the U.S. FDA approval of Apellis’ Syfovre (pegcetacoplan) on February 17th, 2023 for the treatment of geographic atrophy […]

Nearly One Year Post-Launch Biogen & Coherus Biosciences’ Ranibizumab Biosimilars Have Yet to Make a Splash in Their Respective Retina Markets

Uptake and user-base of Byooviz (Biogen) and Cimerli (Coherus) have both been low while general attitudes around biosimilars seem to be cooling, according to a recent analysis from Spherix Global Insights. EXTON, Pa., June 23, 2023 — Spherix has been tracking ophthalmologists’ attitudes and perceptions around biosimilars in their Special Topix: Ophthalmology Biosimilars Today and […]

Genentech’s Vabysmo Boasts Increasingly Favorable Perceptions Among Ophthalmologists for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema, According to Spherix Global Insights

Despite Vabysmo’s positive first impressions, the race is about to heat up with the widely anticipated FDA approval of Regeneron’s 8mg aflibercept potentially around the corner. EXTON, Pa., June 7, 2023 — Genentech’s Vabysmo got an 18-month head start over Regeneron’s high dose Eylea (8mg aflibercept), but that lead time may be coming to a […]

Sign up for alerts, market insights and exclusive content in your inbox.

Spherix is excited to announce our expansion into an additional, rapidly evolving specialty market:


Throughout 2024, we will be publishing over
10 groundbreaking studies covering a wide range of indications within classical hematology.